HOME >> MEDICINE >> NEWS
Leukemia drug breakthrough study in New England Journal of Medicine

Tampa, FL (Feb. 9, 2005) - Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia. Given in pill form, Revlimid simultaneously blocks the growth of new blood vessels that nourish tumors (anti-angiogenesis) and stimulates the immune system to fight cancer cells. The study is reported in the Feb.10 issue of the New England Journal of Medicine.

Nearly 90 percent of MDS patients are anemic and require regular transfusions of red cells. In this study, 91 percent of the MDS patients with a chromosome abnormality named 5q minus syndrome became transfusion independent. The defective 5q chromosome abnormality may be linked to other serious cancers, including leukemias and small cell lung cancer.

In another finding of the same study, all the patients with the 5q deletion who became transfusion independent also went into cytogenetic remission, meaning that the chromosome abnormality disappeared.

List, a professor of interdisciplinary oncology at the University of South Florida, initially developed the phase I clinical trial of Revlimid for treatment of MDS following his laboratory observations that the agent improved the growth of red blood cell precursors from MDS bone marrow. Celgene will submit the seminal findings of List's phase I trial - along with data from two recent confirmatory phase II clinical trials performed nationwide involving more than 350 patients with red blood cell transfusion-dependent MDS - to the U.S. Food and Drug Administration in a new drug application (NDA) for Revlimid as an innovative approach to treat the anemia of MDS patients with the 5q minus deletion.

In 2001, the National Cancer Institute awarded Moffitt the status of a Comprehensive Cancer Center in r
'"/>

Contact: Andrea Brunais
MediaRelations@moffitt.usf.edu
813-632-1478
University of South Florida Health
9-Feb-2005


Page: 1 2

Related medicine news :

1. Leukemia patients survive with stem cell transplant
2. Breakthrough New Therapy Uses Antibody-Targeted Chemotherapy To Fight Leukemia
3. Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients
4. Promising New Drug Uses Antibody Targeted Chemotherapy To Fight Leukemia
5. University of Kentucky Markey Cancer Center Researchers Awarded Grant To Fight Leukemia Recurrence
6. OHSU Scientists Begin Human Trials Of A Drug Aimed At The Underlying Cause Of Chronic Myelogenous Leukemia
7. Fertilization Protein Structure To AID in Leukemia Treatment
8. International gathering of experts to share retinoblastoma breakthroughs
9. Consumers to benefit from organic potato breakthrough
10. Biotech breakthrough in islet cell replacement for type 1 diabetes
11. 4 out of 5 eligible patients missing opportunity to benefit from latest HIV breakthrough

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2020)... ... June 26, 2020 , ... PathAI, a global provider of artificial ... exploratory analysis of digital scoring of PD-L1 expression to assess response in patients treated ... the 2020 American Association for Cancer Research (AACR) Annual Meeting. AACR was held June ...
(Date:6/28/2020)... ... 26, 2020 , ... The Coronavirus pandemic created shortages in ... supplier of top-quality masks, sanitizers and thermometers, Trusted PPE is a woman and ... observed, “All of our masks are manufactured to medical standards in FDA-certified factories, ...
(Date:6/28/2020)... ... 27, 2020 , ... The FSHD Society announced the opening ... the organization’s history. The online conference takes the place of FSHD Connect, the ... year due to COVID-19. Nearly 300 individuals and families living with FSHD are ...
(Date:6/25/2020)... ... June 25, 2020 , ... Pivot Point Consulting, a national ... Firm, expanded its telehealth services to provide end-to-end solutions from strategy ... a Consulting Magazine “2020 Women Leaders in Technology” award winner, Laura Kreofsky ...
(Date:6/24/2020)... ... June 24, 2020 , ... Evolved Naturals, a new ... new website at http://www.evolvednaturals.com The newly launched website showcases a variety of ... oils , and a comprehensive line of skincare & topical products . , ...
Breaking Medicine News(10 mins):
(Date:7/7/2020)... Nova Scotia (PRWEB) , ... July 07, 2020 ... ... rebrand. Established in 2017, the company began as a hair service provider. Now ... both in-office and work-from-home employees. Bright’s expanded offering includes beauty amenities as well ...
(Date:7/2/2020)... (PRWEB) , ... July 02, 2020 , ... ... Look at Medical Conditions that Chiropractors Treat. , “From migraines to anxiety ... certain medical conditions,” according to the company. , Sourced from physician recommendations ...
(Date:7/1/2020)... ... July 01, 2020 , ... Lumeda Inc. (“Lumeda”), ... the formation of its Scientific Advisory Board with the appointment of a panel ... advice to support company development and introduction of its PDT products to the ...
Breaking Medicine Technology:
Cached News: